NCT07863635
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment increased: 300 → 600 participants
- Primary endpoint(s) modified
- Eligibility criteria revised
- Secondary endpoints: 2 to 3
- Notable Recruitment opened
- Primary and study completion dates: Jan 9, 2027 to Dec 11, 2026
- Study sites revised (5)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Geometric Mean Titer (GMT) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation
Timeframe: Day 29
Geometric Mean Fold Rise (GMFR) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation
Timeframe: Day 29
Secondary (3)
Number of Participants with Unsolicited Adverse Events (AEs)
Number of Participants with Serious AEs (SAEs), AEs Leading to Study Withdrawal, and AEs of Special Interest (AESIs)
Seroresponse Rate (SRR) of Neutralizing Antibody (nAb)
Arms and interventions
mRNA-1273 (Variant Formulation)Experimental
Participants will receive a single intramuscular (IM) injection of mRNA-1273 on Day 1.
mRNA-1283 (Variant Formulation)Experimental
Participants will receive a single IM injection of mRNA-1283 on Day 1.
Biologicals: mRNA-1273, mRNA-1283
Sites
5 sites in 1 country